Posted by Michael Wonder on 20 Apr 2020
COVID-19 treatment remedsivir is not available for Australian trial
20 April 2020 - A landmark Australian COVID-19 trial will not get to test the most promising therapy, as it can be revealed there is a worldwide shortage of the experimental treatment.
A landmark Australian COVID-19 trial will not get to test the most promising therapy remedsivir, as it can be revealed there is a worldwide shortage of the experimental treatment.
Gilead which manufacturers remedsivir has told News Corp it will not supply any doses of the drug to the ASCOT trial, a major coronavirus treatment trial to be run in 82 hospitals in Australia and New Zealand.
